Molecular Partners to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 6, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 9:00 AM Pacific Standard Time (12:00 PM Eastern Time; 6:00 PM CET). The presentation, followed by a Q&A session, will...

Read more

Edesa Biotech Announces $4.36 million Registered Direct Offering

January 6, 2020 9:21 AM

TORONTO, ON / ACCESSWIRE / January 6, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors as well as company insiders in a registered direct offering of an aggregate of 1,355,380 common shares. The price per share for investors other than investors that are officers, directors,...

Read more

Experion Announces Leadership Change

January 6, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 6, 2020 / Experion Holdings Ltd. (the "Corporation" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) announces the departure of Chief Executive Officer and director, Jay Garnett, effective January 3, 2020. Experion's board of directors (the "Board") would like to thank Mr. Garnett for his service. The Board has appointed Mr. Jarrett Malnarich as Chief Executive...

Read more

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

December 27, 2019 1:00 AM

ZURICH-SCHLIEREN / ACCESSWIRE / December 27, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug Administration (FDA) for its novel therapeutic, MP0250, for the treatment of Multiple Myeloma. MP0250 is a first-in-class, tri-specific multi-DARPin® drug candidate...

Read more

VenoValve Abstract Published in January 2020 Edition of Journal of Vascular Surgery

December 20, 2019 8:31 AM

Presentation from Abstract to be Delivered at the Southern Association of Vascular Surgery Conference January 8 to 11 in Palm Beach, Florida IRVINE, CA / ACCESSWIRE / December 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that an abstract entitled Results of First-in-Human Implantation of a Prosthetic Venous Valve has been...

Read more

Frelii Announces International License and Profit Sharing Agreement

December 19, 2019 10:45 AM

Frelii Announces International License and Profit Sharing Agreement Company expands its genome discovery AI footprint into Canada LEHI, UT / ACCESSWIRE / December 19, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a License and Profit Sharing...

Read more

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

December 16, 2019 6:20 PM

LONDON, UK / ACCESSWIRE / December 16, 2019 / Midatech (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 11 December 2019, stating that the Company is not in compliance with the minimum bid price requirement set forth in...

Read more

Edesa Biotech Reports Financial Results for Short Period Fiscal Year

December 12, 2019 4:30 PM

TORONTO, ON / ACCESSWIRE / December 12, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the nine-month period ended September 30, 2019 and provided an update on its business. Edesa recently enrolled the first patient in a Phase 2b clinical study of its lead product candidate, EB01. The company is developing EB01 as a monotherapy for patients with chronic allergic...

Read more

DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner

December 12, 2019 8:55 AM

COMPANY TO DISCUSS THIS BUSINESS MOVE IN FURTHER DETAIL EARLY NEXT WEEK, SHORTLY THEREAFTER DECN WILL POST FORECASTS ON ITS WEB SITE LOS ANGELES, CA / ACCESSWIRE / December 12, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory...

Read more

Molecular Partners’ R&D Day in New York City highlights pipeline progress of DARPin(R) therapeutic candidates and provides updates on research activities

December 12, 2019 1:00 AM

Nicolas Leupin, CMO, highlights progress in the development of all three DARPin® product candidates in clinical trials: MP0250 in phase 2 clinical development, MP0274 in phase 1, and MP0310 in co-development with Amgen Recent data presented for MP0250 in relapsed/refractory multiple myeloma at ASH underline the drug's unique ability to complement standard of care through its novel mechanism of action, focusing on the tumor...

Read more

Molecular Partners Presents Updated Results of MP0250 in Patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting

December 7, 2019 7:00 AM

Poster highlights Overall Response Rate (ORR) of 45% in heavily pretreated MM population Strong evidence of durable and deepening responses with ongoing treatment in excess of 9 months in multiple patients, including one patient who achieved a Complete Response (CR) Mechanism of action targeting the microenvironment, inhibiting two signaling pathways, affecting tumor cell growth Additional data to be presented at Molecular Partners'...

Read more

CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

December 6, 2019 9:00 AM

VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10, 2019 at 2:00 PM PST or 5:00 PM EST. The Chief Executive Officer, Geert Kersten, will be presenting and meeting with investors. To access the live webcast and subsequent archived recordings for the...

Read more

Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer

December 5, 2019 9:10 AM

LONDON, UK / ACCESSWIRE / December 5, 2019 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has received confirmation of a €2.6 million EU grant to be used to conduct a ground-breaking clinical study, GlioKIDS, designed to demonstrate the efficacy of...

Read more

American CryoStem Corporation Issues Shareholder Letter

December 5, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / December 5, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, issues the following letter on behalf of the CEO: Dear Fellow Shareholders: Business Partners and Friends: Nearing the end of 2019, I want to take this...

Read more

Updated Invitation & Agenda for Molecular Partners R&D Day 2019 - Dec. 12, 2019 - 7.30-10.00am - NYC

December 3, 2019 11:30 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 3, 2019 / Molecular Partners AG (SIX:MOLN) Invitation We're looking forward to welcoming you at Molecular Partners' R&D Day on Thursday, December 12, 2019 from 7:30am to 10:00am. The event will take place at The Yale Club, 50 Vanderbilt Avenue, New York City. Click here for directions. Below is a detailed agenda of the event. If you have any questions about the event...

Read more

Artelo Biosciences to Present at the 12th Annual LD Micro Main Event

December 3, 2019 9:00 AM

LA JOLLA, CA / ACCESSWIRE / December 3, 2019 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Air, California. Gregory D. Gorgas, President and Chief Executive Officer of Artelo...

Read more

Edesa Biotech Reports Positive Healthy Volunteer Data and Expands Phase 2b Dermatitis Study to Patients with Facial Lesions

December 3, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / December 3, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported that the company's lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clinical study in chronic allergic contact dermatitis (ACD), a debilitating disease that is frequently caused by allergens present in the workplace. The...

Read more

SHAREHOLDER ALERT: COF MTCH PRU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

December 2, 2019 3:20 PM

NEW YORK, NY / ACCESSWIRE / December 2, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. Capital One Financial Corporation (NYSE:COF) If you suffered a loss, contact us at:...

Read more

Molecular Partners to Participate in the Evercore ISI HealthCONx Conference

December 2, 2019 11:30 AM

ZURICH-SCHLIEREN / ACCESSWIRE / December 2, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 12:50 - 1:20 PM Eastern Time (6:50 PM CET). The event will take...

Read more

Proteros, co-founder of Rodin Therapeutics, announces Rodin's acquisition by Alkermes

November 28, 2019 3:15 AM

MUNICH, GERMANY / ACCESSWIRE / November 28, 2019 / Proteros biostructures GmbH today announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland. Rodin has been co-founded by Proteros in 2013. Rodin's security holders will receive an upfront payment of $100...

Read more